Across TCGA pan-cancer cohorts, GIMAP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GIMAP1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GIMAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GIMAP1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

COAD, UCEC, and LUAD are the cancer types where GIMAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	All	0.803	1.000	.009	114	view →
UCEC	DFS	Tertile	All	0.807	0.979	.009	24	view →
LUAD	DFS	Tertile	All	0.828	0.547	.009	6	view →
PDAC	DFS	Median	III,IV	0.548	0.164	.002	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GIMAP1 tumor-vs-normal RNA expression · all GIMAP1 data types